Skip to content
  • Monday, 12 October 2026
  • 9:01 pm
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • Ionis Forecasts $2 Billion Peak Sales for Tryngolza, Leveraging First-Mover Advantage in Severe Hypertriglyceridemia
Pharmaceutical R&D

Ionis Forecasts $2 Billion Peak Sales for Tryngolza, Leveraging First-Mover Advantage in Severe Hypertriglyceridemia

Teuku Ryan Jun 27, 2026 0

Ionis Pharmaceuticals is poised to redefine its market position with ambitious peak sales forecasts of $2 billion for its newly…

Read More
Data Science & Bioinformatics

Leveraging Mimesis for Secure Data Science: A Comprehensive Guide to Anonymizing Production Data.

Evan Lee Salim May 20, 2026 0

In an increasingly data-driven world, the ability to harness the power of vast datasets is paramount for innovation, yet it…

Read More
Science News: A Century of Empowering Public Understanding of ScienceThe Intertwined Path of Metabolic and Cognitive Health Understanding the Multi-Faceted Link Between Diabetes and Dementia RiskCompetition Between Amyloid Beta and Tau for Microtubule Binding Sites Offers New Insight into the Early Pathogenesis of Alzheimer’s DiseaseArtificial Intelligence Systems Struggle with Cognitive Focus and Distraction Management in New Research Study
The Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals PlummetJapan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactMEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthEliquis Loss of Exclusivity: A Pharmaceutical Patent Cliff of Historic Proportions
2026 PharmSci 360 adds tracks on research credibility and post-animal drug developmentTeva Pharmaceutical Industries Secures FDA Approval for Weltruza, a Once-Monthly Injectable Olanzapine to Transform Schizophrenia CareTWiV 1288: Clinical update with Dr. Daniel Griffin | Microbe TVScientists discover a hidden factor that can make or break chemical reactions
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
2026 PharmSci 360 adds tracks on research credibility and post-animal drug development
Lana Keisha Oct 12, 2026
Pharmaceutical R&D
Teva Pharmaceutical Industries Secures FDA Approval for Weltruza, a Once-Monthly Injectable Olanzapine to Transform Schizophrenia Care
Teuku Ryan Oct 12, 2026
Microbiology & Immunology
TWiV 1288: Clinical update with Dr. Daniel Griffin | Microbe TV
Lina Irawan Oct 12, 2026
Advanced Materials Science
Scientists discover a hidden factor that can make or break chemical reactions
Nila Kartika Wati Oct 12, 2026

Copyright © 2026 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ